Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Lukas Krauß

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0062-8685; OpenAlex author ID A5005924562. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. Co-author DOI 10.1158/2767-9764.crc-25-0670↗
  3. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  4. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  5. Epigenetic control of pancreatic cancer metastasis. Co-author DOI 10.1007/s10555-023-10132-z↗
  6. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  7. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  8. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  9. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carolin Schneider · 9 shared papers, 2022–2026 · strength 1.42
  2. Günter Schneider · 9 shared papers, 2022–2026 · strength 1.42
  3. Dieter Saur · 9 shared papers, 2022–2026 · strength 1.42
  4. Maximilian Reichert · 8 shared papers, 2022–2026 · strength 1.19
  5. Matthias Wirth · 8 shared papers, 2022–2026 · strength 1.19
  6. Elisabeth Heßmann · 6 shared papers, 2022–2026 · strength 1.07
  7. Christian Schneeweis · 6 shared papers, 2022–2026 · strength 0.86
  8. Marian Grade · 5 shared papers, 2022–2026 · strength 0.83
  9. Roland Rad · 6 shared papers, 2022–2026 · strength 0.81
  10. Michael B. Ghadimi · 4 shared papers, 2024–2026 · strength 0.71
  11. Volker Ellenrieder · 4 shared papers, 2024–2026 · strength 0.71
  12. Felix Orben · 4 shared papers, 2022–2026 · strength 0.57
  13. Oliver Holger Krämer · 4 shared papers, 2022–2026 · strength 0.56
  14. Constanza Tapia Contreras · 3 shared papers, 2024–2026 · strength 0.50
  15. Zonera Hassan · 4 shared papers, 2022 · strength 0.48
  16. Roland Michael Schmid · 3 shared papers, 2022–2026 · strength 0.41
  17. Lena‐Christin Conradi · 2 shared papers, 2025–2026 · strength 0.38
  18. Janine Murr · 2 shared papers, 2022–2026 · strength 0.30
  19. Chiara Falcomatà · 2 shared papers, 2022–2024 · strength 0.26
  20. Bernhard Küster · 2 shared papers, 2022–2024 · strength 0.25
  21. Katharina Lankes · 2 shared papers, 2022 · strength 0.23
  22. Valentina Spielmann · 1 shared paper, 2026 · strength 0.21
  23. Ulrich Bernd Keller · 1 shared paper, 2026 · strength 0.19
  24. Hazal Köse · 1 shared paper, 2026 · strength 0.19
  25. Alexandra Nguyen · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.